Wednesday, 5 February 2020

Novo Nordisk sees slower 2020 growth with US insulin prices pressured

Diabetes drug maker Novo Nordisk said on Wednesday it expects its business to grow at a slower pace in 2020 compared to last year with insulin prices in the U.S. likely to remain under pressure.

from Earnings https://ift.tt/2UtzlzI
via IFTTT

No comments:

Post a Comment